Bust #5: The Clear-Skin Song, Slowed Way Down

🎬 Bust #5 · The Commercial As You See It

Clear Skin, Short Sleeves, And A Song You Cannot Unhear

Today's bust is the prescription-drug commercial with one of the catchiest songs on television: the ads for SKYRIZI® (risankizumab-rzaa). The mood is pure summer postcard — smiling people, sunshine, short sleeves worn with total confidence, and a cheerful sing-along feeling that says clear skin is simply what life looks like now.

Then the mood changes lanes. While the smiles keep smiling, a much faster voice — the famous “major risk” voiceover — starts sprinting through infections, tuberculosis checks, vaccines, and allergic reactions, while tiny text tiptoes along the bottom of the screen.

To be fair — and we are always fair here — those warnings ARE in the commercial. The law requires them for prescription-drug ads. They are just delivered at auctioneer speed, in ant-sized type, underneath a song engineered to stay in your head long after the warnings have left it. So today, we slow the whole thing waaay down.

🔍 The Fine Print, Slowed Waaay Down

What That Fast Voice Is Actually Saying

Here is the fast part, translated into normal human English, based on the FDA-approved prescribing information for this medicine (DailyMed label, revised June 2026):

• “It may increase the risk of infection.” The label says this medicine may increase the risk of infection, that patients should be told to seek medical advice if signs or symptoms of an important infection show up, and that if such an infection develops, the medicine should not be given again until the infection resolves.
• “You should be evaluated for TB before starting.” That TB is tuberculosis. The label says patients should be evaluated for TB infection before treatment begins — this is a step that happens before the happy part starts, not an afterthought.
• “Avoid live vaccines.” The label's immunization warning says to avoid the use of live vaccines during treatment, and its pre-treatment checklist includes completing age-appropriate vaccinations as recommended by current guidelines.
• “Serious allergic reactions can happen.” The label warns that serious hypersensitivity reactions, including anaphylaxis, may occur — and says the medicine must not be used by people who have had a serious hypersensitivity reaction to it or its ingredients.
• “Liver problems were reported during the starting phase for bowel conditions.” For the Crohn's disease and ulcerative colitis uses, the label reports drug-induced liver injury during induction (starting) treatment, and calls for monitoring liver enzymes and bilirubin at the start and during induction for at least the first twelve weeks.
• “The common side effects are…” For plaque psoriasis and psoriatic arthritis, the label lists the most common reactions (occurring in at least 1% of patients) as upper respiratory infections, headache, fatigue, injection-site reactions, and tinea (fungal) infections. That list goes by in the ad in roughly one breath.

None of that means the medicine is “bad.” It means it is a real prescription medicine that works on the immune system, with real benefits for the right patients and real warnings that deserve more than a speed-read under a sing-along.

🧠 What The Song Doesn't Spell Out

The Three Things The Sunshine Doesn't Tell You

1. Who it is actually approved for. The label lists specific uses, and “I'd like clearer skin” is not one of them. SKYRIZI is approved for moderate-to-severe plaque psoriasis in adults and children age 6 and older who are candidates for systemic therapy (injections or pills) or phototherapy (light treatment); for active psoriatic arthritis in adults and children age 6 and older; and, in adults only, for moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis. Mild cases and casual curiosity are not the labeled audience — a clinician has to place a patient in one of those groups.

2. Why the infection warnings are there at all. The label describes this medicine as an interleukin-23 antagonist — in plain English, it deliberately dials down one specific signal in the immune system. That is the whole idea of the drug, and it is also exactly why the label spends so much time on infections, TB screening, and vaccines. The fast voice is not reading random legal trivia; it is describing the trade-off built into how the medicine works.

3. What the commitment actually looks like. For plaque psoriasis, the labeled schedule is an injection at week 0, another at week 4, and then one every 12 weeks after that — an ongoing prescription routine, not a one-time fix. For Crohn's disease and ulcerative colitis, treatment starts with intravenous infusions given in a healthcare facility, followed by maintenance injections. And, as with nearly every commercial in this series, the ad says nothing about price, insurance coverage, or approvals — the song sells the feeling, and the pharmacy and coverage conversation happens later, off camera.

⚖️ The Busters Verdict

Verdict: The Truth Was There — It Was Just Singing Backup

This commercial does not hide its warnings in a vault. It does something sneakier and completely legal: it puts the sunshine, the sleeves, and the song up front, and the immune-system fine print in the back, read at full sprint in print sized for a magnifying glass. Slowed down, the label tells a much more specific story — a defined set of conditions, a screening step before starting, vaccine rules, and a long-term dosing schedule.

So here is your Commercial Busters homework — the questions worth taking to a doctor or pharmacist, because they are the professionals and we are not:

• “Am I actually in one of the groups this medicine is labeled for?”
• “What screening — including TB evaluation — happens before a first dose?”
• “Which of my vaccines need attention before treatment could start?”
• “What infection symptoms should make me call you right away?”
• “What would the ongoing schedule — and the cost with my coverage — actually look like?”

Sources you can check yourself: the FDA-approved full prescribing information and Medication Guide for SKYRIZI (risankizumab-rzaa), revised June 2026, published on DailyMed (U.S. National Library of Medicine): DailyMed — SKYRIZI prescribing information (PDF). Every label claim above — the approved uses, the infection, tuberculosis, vaccine and liver warnings, the common reactions, and the dosing schedules — comes from that document.

Final reminder: This post is for educational and entertainment purposes only. It is not medical, financial, legal, insurance, or any other professional advice, and it should not be used to make any kind of decision. Talk to a qualified professional about your own situation. Please do not contact us about the products, drugs, policies, or services covered here — we do not provide advice on any of them.